[go: up one dir, main page]

WO2011034582A3 - Anticorps anti-vih-1 - Google Patents

Anticorps anti-vih-1 Download PDF

Info

Publication number
WO2011034582A3
WO2011034582A3 PCT/US2010/002515 US2010002515W WO2011034582A3 WO 2011034582 A3 WO2011034582 A3 WO 2011034582A3 US 2010002515 W US2010002515 W US 2010002515W WO 2011034582 A3 WO2011034582 A3 WO 2011034582A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/002515
Other languages
English (en)
Other versions
WO2011034582A2 (fr
Inventor
Barton F. Haynes
Georgia Tomaras
Shaunna Shen
Dimiter S. Dimitrov
Zhongyu Zhu
Kwan-Ki Hwang
Nicholas Chiorazzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Duke University
US Department of Health and Human Services
Original Assignee
Feinstein Institutes for Medical Research
Duke University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research, Duke University, US Department of Health and Human Services filed Critical Feinstein Institutes for Medical Research
Priority to CA2774446A priority Critical patent/CA2774446A1/fr
Priority to AU2010296058A priority patent/AU2010296058A1/en
Priority to EP10817555A priority patent/EP2477658A2/fr
Priority to JP2012529742A priority patent/JP2013505236A/ja
Publication of WO2011034582A2 publication Critical patent/WO2011034582A2/fr
Publication of WO2011034582A3 publication Critical patent/WO2011034582A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2010/002515 2009-09-16 2010-09-16 Anticorps anti-vih-1 Ceased WO2011034582A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2774446A CA2774446A1 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1
AU2010296058A AU2010296058A1 (en) 2009-09-16 2010-09-16 HIV-1 antibodies
EP10817555A EP2477658A2 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1
JP2012529742A JP2013505236A (ja) 2009-09-16 2010-09-16 Ｈｉｖ−１抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27234909P 2009-09-16 2009-09-16
US61/272,349 2009-09-16
US24879609P 2009-10-05 2009-10-05
US61/248,796 2009-10-05

Publications (2)

Publication Number Publication Date
WO2011034582A2 WO2011034582A2 (fr) 2011-03-24
WO2011034582A3 true WO2011034582A3 (fr) 2011-09-15

Family

ID=43759219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002515 Ceased WO2011034582A2 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1

Country Status (5)

Country Link
EP (1) EP2477658A2 (fr)
JP (1) JP2013505236A (fr)
AU (1) AU2010296058A1 (fr)
CA (1) CA2774446A1 (fr)
WO (1) WO2011034582A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
CA2979708A1 (fr) 2015-03-19 2016-09-22 Duke University Anticorps neutralisant le vih-1 et leurs utilisations
PE20210685A1 (es) 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso
EP3999107A1 (fr) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Vaccins contre le vih et leurs procédés de fabrication et d'utilisation
CA3187085A1 (fr) 2020-08-25 2022-03-03 Manuel Baca Molecules de liaison a un antigene multi-specifiques ciblant le vih et methodes d'utilisation
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
WO2024097957A1 (fr) * 2022-11-03 2024-05-10 Duke University Nouveaux anticorps contre le vih et leurs procédés de fabrication et d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081723A1 (en) * 1995-06-07 2002-06-27 Peter Brams Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006110831A2 (fr) * 2005-04-12 2006-10-19 Duke University Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081723A1 (en) * 1995-06-07 2002-06-27 Peter Brams Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006110831A2 (fr) * 2005-04-12 2006-10-19 Duke University Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VIDAR WENDEL-HANSEN ET AL.: "Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines.", LEUKEMIA, vol. 8, no. 3, 1994, pages 476 - 484, XP008154323 *
XIAOYING SHEN ET AL.: "In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.", JOURNAL OF VIROLOGY, vol. 83, no. 8, April 2009 (2009-04-01), pages 3617 - 3625, XP008154322 *

Also Published As

Publication number Publication date
CA2774446A1 (fr) 2011-03-24
WO2011034582A2 (fr) 2011-03-24
JP2013505236A (ja) 2013-02-14
AU2010296058A1 (en) 2012-05-03
EP2477658A2 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
AU2013207589A1 (en) Anti-Siglec-15 Antibody
EP3514173B8 (fr) Anticorps contre dkk-1
WO2011034582A3 (fr) Anticorps anti-vih-1
AU2009100437A4 (en) Pippetop
AU2009100982A4 (en) Flip - barbi
AU2009101120A4 (en) Koolkilt
AU2009100848A4 (en) Headbags
AU2009100147A4 (en) Safetank
AU2009100680A4 (en) Ezy-Lay
AU2009100423A4 (en) Byak
AU2009101028A4 (en) Hybridtelerent
AU2009100472A4 (en) Duramind
AU2009100092A4 (en) Interfilm
AU2009100564A4 (en) Agwave
AU2009100549A4 (en) XBlend
HK1188718A (en) Antibodies
HK1190730A (zh) 抗缺刻蛋白1抗体
HK1146067A (en) Anti-tyrp1 antibodies
AU2009901784A0 (en) Fresholite
AU2009900936A0 (en) HatStick
AU2009901300A0 (en) Thermomoulding
AU2009901157A0 (en) MaxxSlam
AU2009901142A0 (en) Impellernut
AU2008906662A0 (en) Cami-ette
AU2009901345A0 (en) Camsok

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10817555

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2012529742

Country of ref document: JP

Ref document number: 2774446

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010817555

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010296058

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010296058

Country of ref document: AU

Date of ref document: 20100916

Kind code of ref document: A